Abstract | BACKGROUND: METHODS: The initial study (NCT01324128) and its extension (NCT01464190) were multicenter, Phase 3, open-label, randomized (2:1), active-controlled trials comparing sucroferric oxyhydroxide (1.0-3.0 g/day) with sevelamer (2.4-14.4 g/day) in dialysis patients over 52 weeks in total. RESULTS: CONCLUSIONS:
|
Authors | Jürgen Floege, Adrian C Covic, Markus Ketteler, Johannes Mann, Anjay Rastogi, Bruce Spinowitz, Viatcheslav Rakov, Laura J Lisk, Stuart M Sprague |
Journal | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
(Nephrol Dial Transplant)
Vol. 32
Issue 11
Pg. 1918-1926
(Nov 01 2017)
ISSN: 1460-2385 [Electronic] England |
PMID | 28339993
(Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Copyright | © The Author 2017. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. |
Chemical References |
- Drug Combinations
- Ferric Compounds
- Phosphates
- sucroferric oxyhydroxide
- Sucrose
|
Topics |
- Adult
- Aged
- Combined Modality Therapy
- Drug Combinations
- Female
- Ferric Compounds
(adverse effects, therapeutic use)
- Humans
- Hyperphosphatemia
(blood, drug therapy, etiology)
- Male
- Medication Adherence
- Middle Aged
- Peritoneal Dialysis
- Phosphates
(blood)
- Sucrose
(adverse effects, therapeutic use)
- Treatment Outcome
|